• Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274: 17159-17163 (1999). *

• Adachi T, Nakagawa H, Hagiya Y, Yasuoka T, Ishikawa T. Transport-metabolism interplay: LXR-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells. Mol. Pharm. 6: 1678-1688 (2009). *

• Adachi Y, Kamisako T. Intrahepatic cholestasis. Nippon Rinsho 54: 788-793 (1996).

• Adachi Y, Kamisako T, Okuyama Y, Miya H. Hepatic metabolism and transport of bilirubin and other organic anions. Nippon Rinsho 54: 2276-2290 (1996).

• Akashi M, Tanaka A, Takikawa H. Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats. Hepatol. Res. 34: 193-198 (2006).

• Aleksandrov AA, Aleksandrov LA, Riordan JR. CFTR (ABCC7) is a hydrolyzable-ligand-gated channel. Pflugers Arch. 453: 693-702 (2007). *

• Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24: 1803-1823 (2007). *

• Andrejko KM, Raj NR, Kim PK, Cereda M, Deutschman CS. IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock 29: 490-496 (2008). *

• Anzai N, Kanai Y, Endou H. Organic anion transporter family: current knowledge. J. Pharmacol. Sci. 100: 411-426 (2006). *

• Aoki K, Saso N, Kato S, Sugiyama Y, Sato H. Nitric oxide and peroxynitrite regulate transporter transcription in rat liver slices. Biol. Pharm. Bull. 31: 1882-1887 (2008). *

• Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 9: 558-564 (2003). *

• Asif AR, Ljubojevic M, Sabolic I, Shnitsar V, Metten M, Anzai N, Mueller GA, Burckhardt G, Hagos Y. Regulation of steroid hormone biosynthesis enzymes and organic anion transporters by forskolin and DHEAS treatment in adrenocortical cells. Am. J. Physiol. Endocrinol. Metab. 291: E1351-E1359 (2006). *

• Aslamkhan AG, Thompson DM, Perry JL, Bleasby K, Wolff NA, Barros S, Miller DS, Pritchard JB. The flounder organic anion transporter fOat has sequence, function and substrate specificity similarity to both mammalian Oat1 and Oat3. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291: R1773-R1780 (2006). *

• Augustine LM, Markelewicz RJ Jr, Boekelheide K, Cherrington NJ. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab. Dispos. 33: 182-189 (2005). *

• Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM. Interaction of methotrexate with OATP1A2 and its genetic variants. J. Pharmacol. Exp. Ther. 318: 521-529 (2006). *

• Bahn A, Ebbinghaus C, Ebbinghaus D, Ponimaskin EG, Fuzesi L, Burckhardt G, Hagos Y. Expression studies and functional characterization of renal human organic anion transporter 1 isoforms. Drug Metab. Dispos. 32: 424-430 (2004). *

• Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, Krick W, Burckhardt BC, Sabolic I, Burckhardt G. Identification of a new urate and high affinity nicotinate transporter - human organic anion transporter 10 (hOAT10, SLC22A13). J. Biol. Chem. 283: 16332-16341 (2008). *

• Bahn A, Hagos Y, Rudolph T, Burckhardt G. Mutation of amino acid 475 of rat organic cation transporter 2 (rOCT2) impairs organic cation transport. Biochimie 86: 133-136 (2004).

• Baier PK, Hempel S, Waldvogel B, Baumgartner U. Zonation of hepatic bile salt transporters. Dig. Dis. Sci. 51: 587-593 (2006). *

• Ballatori N. Biology of a novel organic solute and steroid transporter, OSTalpha-OSTbeta. Exp. Biol. Med. (Maywood) 230: 689-698 (2005). *

• Ballatori N, Hammond CL, Cunningham JB, Krance SM, Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 204: 238-255 (2005). *

• Ballatori N, Henson JH, Seward DJ, Cai SY, Runnegar M, Fricker G, Miller DS, Boyer JL. Retention of structural and functional polarity in cultured skate hepatocytes undergoing in vitro morphogenesis. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 144: 167-179 (2006). *

• Barros SA, Srimaroeng C, Perry JL, Walden R, Dembla-Rajpal N, Sweet DH, Pritchard JB. Activation of protein kinase C zeta increases OAT1 (SLC22A6) and OAT3 (SLC22A8)-mediated transport. J. Biol. Chem. 284: 2672-2679 (2009). *

• Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *

• Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy 28: 883-894 (2008).

• Beuers U. Mechanisms of action of ursodeoxycholic acid in cholestasis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 49-50. October 15-16 (2003). *

• Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33: 1206-1216 (2001). *

• Beukeveld GJ, In 't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J. Hepatol. 24: 343-352 (1996). *

• Bhatnagar V, Xu G, Hamilton BA, Truong DM, Eraly SA, Wu W, Nigam SK. Analyses of 5' regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3). J. Hum. Genet. 51: 575-580 (2006). *

• Bjornsson E, Chapman RW. Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275 (2003).

• Bloomer J, Wang Y, Singhal A, Risheg H. Molecular studies of liver disease in erythropoietic protoporphyria. J. Clin. Gastroenterol. 39: S167-S175 (2005).

• Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *

• Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278: 23529-23537 (2003). *

• Bolder U, Jeschke MG, Landmann L, Wolf F, de Sousa C, Schlitt HJ, Przkora R. Heat stress enhances recovery of hepatocyte bile acid and organic anion transporters in endotoxemic rats by multiple mechanisms. Cell Stress Chaperones 11: 89-100 (2006). *

• Bolder U, Thasler WE, Hofmann AF, Jauch KW. Hepatocellular transport of bile acids and organic anions in infection and SIRS - evidence for different mechanisms for regulating membrane transport proteins. Langenbecks Arch. Chir. Suppl. Kongressbd. 115 (Suppl. I): 391-396 (1998).

• Bolder U, Ton-Nu HT, Schteingart CD, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 112: 214-225 (1997). *

• Bolder U, Trang NV, Hagey LR, Schteingart CD, Ton-Nu HT, Cerre C, Elferink RP, Hofmann AF. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 117: 962-971 (1999). *

• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92: 1295-1302 (2000). *

• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *

• Boyer JL, Denk G, Bohan A, Chen WS, Soroka C, Denson L. Adaptive regulation of bile salt transporters in cholestasis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 46-47. June 18-19 (2004). *

• Brandoni A, Anzai N, Kanai Y, Endou H, Torres AM. Renal elimination of p-aminohippurate (PAH) in response to three days of biliary obstruction in the rat. The role of OAT1 and OAT3. Biochim. Biophys. Acta 1762: 673-682 (2006). *

• Brandoni A, Torres AM. Characterization of the mechanisms involved in the increased renal elimination of bromosulfophthalein during cholestasis: involvement of Oatp1. J. Histochem. Cytochem. 57: 449-456 (2009). *

• Brandoni A, Villar SR, Picena JC, Anzai N, Endou H, Torres AM. Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction. Hepatology 43: 1092-1100 (2006). *

• Breen CM, Sykes DB, Baehr C, Fricker G, Miller DS. Fluorescien-methotrexate transport in rat choroid plexus analyzed using confocal microscopy. Am. J. Physiol. Renal Physiol. 287: F562-F569 (2004). *

• Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San Martin FG, Marin JJ. OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J. Biol. Chem. 281: 30326-30335 (2006). *

• Capuano P, Bacic D, Stange G, Hernando N, Kaissling B, Pal R, Kocher O, Biber J, Wagner CA, Murer H. Expression and regulation of the renal Na/phosphate cotransporter NaPi-IIa in a mouse model deficient for the PDZ protein PDZK1. Pflugers Arch. 449: 392-402 (2005). *

• Cha SH, Lee WK, Kwak JO, Hwang JS, Suh CK. Identification and characterization of single nucleotide polymorphisms of SLC22A11 (hOAT4) in Korean women osteoporosis patients. Mol. Cells 25: 265-271 (2008).

• Chae HW, Kim IW, Jin HE, Kim DD, Chung SJ, Shim CK. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch. Pharm. Res. 31: 103-110 (2008).

• Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21: 719-735 (2004). *

• Chandra P, Johnson BM, Zhang P, Pollack GM, Brouwer KL. Modulation of hepatic canalicular or basolateral transport alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metab. Dispos. 33: 1238-1243 (2005). *

• Chen BC, Kuo KK, Chen YH, Liu CH, Tsai LY, Hsu HK, Hsu C. Retinoid X receptor alpha participation in dexamethasone induced rat bile acid coenzyme A-amino acid N-acyltransferase expression in septic liver. Shock 32: 164-171 (2009).

• Chen C, Cheng X, Dieter MZ, Tanaka Y, Klaassen CD. Activation of cyclic AMP (cAMP)-dependent signaling pathway induces mouse organic anion transporting polypeptide 2 (Oatp2) expression. Mol. Pharmacol. 71: 1159-1164 (2007). *

• Chen HL, Liu YJ, Chen HL, Wu SH, Ni YH, Ho MC, Lai HS, Hsu WM, Tseng HC, Jeng YM, Chang MH. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr. Res. 63: 667-673 (2008). *

• Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *

• Chen J, Terada T, Ogasawara K, Katsura T, Inui KI. Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am. J. Physiol. Renal Physiol. 295: F247-F252 (2008). *

• Cheng X, Klaassen CD. Critical role of PPARalpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced down-regulation of Oatp uptake transporters in mouse livers. Toxicol. Sci. 106: 37-45 (2008). *

• Cheng X, Maher JM, Dieter MZ, Klaassen CD. Regulation of mouse organic anion transporting polypeptides (Oatps) in liver by prototypical microsome enzyme inducers that activate distinct transcription factor pathways. Drug Metab. Dispos. 33: 1276-1282 (2005). *

• Cheng X, Maher JM, Lu H, Klaassen CD. Endocrine regulation of gender-divergent mouse organic anion transporting polypeptide (Oatp) expression. Mol. Pharmacol. 70: 1291-1297 (2006). *

• Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 32: 734-741 (2004). *

• Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40: 539-551 (2004). *

• Chignard N, Mergey M, Veissiere D, Parc R, Capeau J, Poupon R, Paul A, Housset C. Bile acid transport and regulating functions in the human biliary epithelium. Hepatology 33: 496-503 (2001). *

• Choudhuri S, Cherrington NJ, Li N, Klaassen CD. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab. Dispos. 31: 1337-1345 (2003). *

• Chu X, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human renal transporters hOAT3, OATP4C1, and MDR1 P-glycoprotein. J. Pharmacol. Exp. Ther. 321: 673-683 (2007). *

• Clerici C, Castellani D, Asciutti S, Pellicciari R, Setchell KD, O'Connell NC, Sadeghpour B, Camaioni E, Fiorucci S, Renga B, Nardi E, Sabatino G, Clementi M, Giuliano V, Baldoni M, Orlandi S, Mazzocchi A, Morelli A, Morelli O. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats. Toxicol. Appl. Pharmacol. 214: 199-208 (2006). *

• Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 27: 438-446 (2006). *

• Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 15: 523-533 (2005).

• Conseil G, Deeley RG, Cole SP. Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1). J. Biol. Chem. 281: 43-50 (2006). *

• Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrie A. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9: 1217-1227 (2008).

• Cui T, Liu Y, Men X, Xu Z, Wu L, Liu S, Xing A. Bile acid transport correlative protein mRNA expression profile in human placenta with intrahepatic cholestasis of pregnancy. Saudi Med. J. 30: 1406-1410 (2009).

• Cui Y, Konig J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol. 60: 934-943 (2001). *

• Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276: 9626-9630 (2001). *

• Cui Y, Konig J, Nies AT, Pfannschmidt M, Hergt M, Franke WW, Alt W, Moll R, Keppler D. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 83: 527-538 (2003).

• Dawson PA, Lan T, Rao A. Bile acid transporters. J. Lipid Res. 50: 2340-2357 (2009). *

• Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 580: 1103-1111 (2006). *

• Deguchi T, Isozaki K, Yousuke K, Terasaki T, Otagiri M. Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. J. Neurochem. 96: 1051-1059 (2006).

• Denk GU, Soroka CJ, Mennone A, Koepsell H, Beuers U, Boyer JL. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology 39: 1382-1389 (2004). *

• Denson LA, Auld KL, Schiek DS, McClure MH, Mangelsdorf DJ, Karpen SJ. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J. Biol. Chem. 275: 8835-8843 (2000). *

• Denson LA, Bohan A, Held MA, Boyer JL. Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis. Gastroenterology 123: 599-607 (2002). *

• Diaz GJ. Basolateral and canalicular transport of xenobiotics in the hepatocyte: a review. Cytotechnology 34: 225-235 (2000). *

• Diena T, Melani R, Caci E, Pedemonte N, Sondo E, Zegarra-Moran O, Galietta LJ. Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins. Eur. J. Pharmacol. 560: 127-131 (2007). *

• Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 167: 73-81 (2001). *

• Ding X, Lichti K, Kim I, Gonzalez FJ, Staudinger JL. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Biol. Chem. 281: 26540-26551 (2006). *

• Donner MG, Schumacher S, Warskulat U, Heinemann J, Haussinger D. Obstructive cholestasis induces TNF-alpha- and IL-1beta-mediated periportal down-regulation of Bsep and zonal regulation of Ntcp, Oatp1a4 and Oatp1b2. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1134-G1146 (2007). *

• Dransfeld O, Gehrmann T, Kohrer K, Kircheis G, Holneicher C, Haussinger D, Wettstein M. Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int. 25: 1243-1258 (2005). *

• Dumont M, Jacquemin E, D'Hont C, Descout C, Cresteil D, Haouzi D, Desrochers M, Stieger B, Hadchouel M, Erlinger S. Expression of the liver Na+-independent organic anion transporting polypeptide (oatp-1) in rats with bile duct ligation. J. Hepatol. 27: 1051-1056 (1997). *

• Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433: 397-412 (2005). *

• Elwi AN, Damaraju VL, Baldwin SA, Young JD, Sawyer MB, Cass CE. Renal nucleoside transporters: physiological and clinical implications. Biochem. Cell. Biol. 84: 844-858 (2006). *

• Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin. Exp. Nephrol. 9: 195-205 (2005). *

• Eraly SA, Bush KT, Sampogna RV, Bhatnagar V, Nigam SK. The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol. Pharmacol. 65: 479-487 (2004). *

• Eraly SA, Hamilton BA, Nigam SK. Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem. Biophys. Res. Commun. 300: 333-342 (2003). *

• Eraly SA, Monte JC, Nigam SK. Novel slc22 transporter homologs in fly, worm, and human clarify the phylogeny of organic anion and cation transporters. Physiol. Genomics 18: 12-24 (2004). *

• Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am. J. Physiol. Renal Physiol. 290: F905-F912 (2006). *

• Erlinger S. Mechanisms of hepatic transport and bile secretion. Acta Gastroenterol. Belg. 59: 159-162 (1996).

• Erlinger S. Review article: new insights into the mechanisms of hepatic transport and bile secretion. J. Gastroenterol. Hepatol. 11: 575-579 (1996).

• Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 55: 107-124 (2003). *

• Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32: 82-86 (2000). *

• Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am. J. Pathol. 168: 410-422 (2006). *

• Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121: 170-183 (2001). *

• Frank C, Makkonen H, Dunlop TW, Matilainen M, Vaisanen S, Carlberg C. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J. Mol. Biol. 346: 505-519 (2005). *

• Friesema EC, Jansen J, Milici C, Visser TJ. Thyroid hormone transporters. Vitam. Horm. 70: 137-167 (2005).

• Friesema ECh, Jansen J, Heuer H, Trajkovic M, Bauer K, Visser TJ. Mechanisms of disease: psychomotor retardation and high T(3) levels caused by mutations in monocarboxylate transporter 8. Nat. Clin. Pract. Endocrinol. Metab. 2: 512-523 (2006). *

• Fujiyama N, Shitara Y, Ito K, Masubuchi Y, Horie T. Down-regulation of hepatic transporters for BSP in rats with indomethacin-induced intestinal injury. Biol. Pharm. Bull. 30: 556-561 (2007). *

• Furihata T, Satoh T, Yamamoto N, Kobayashi K, Chiba K. Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm. Res. 24: 2327-2332 (2007). *

• Gao B, St Pierre MV, Stieger B, Meier PJ. Differential expression of bile salt and organic anion transporters in developing rat liver. J. Hepatol. 41: 201-208 (2004). *

• Gartung C, Matern S. Molecular regulation of sinusoidal liver bile acid transporters during cholestasis. Yale J. Biol. Med. 70: 355-363 (1997).

• Gatmaitan ZC, Nies AT, Arias IM. Regulation and translocation of ATP-dependent apical membrane proteins in rat liver. Am. J. Physiol. 272: G1041-G1049 (1997).

• Geier A, Dietrich CG, Gerloff T, Haendly J, Kullak-Ublick GA, Stieger B, Meier PJ, Matern S, Gartung C. Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochim. Biophys. Acta 1609: 87-94 (2003). *

• Geier A, Dietrich CG, Grote T, Beuers U, Prufer T, Fraunberger P, Matern S, Gartung C, Gerbes AL, Bilzer M. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol. 43: 1021-1030 (2005). *

• Geier A, Dietrich CG, Lammert F, Orth T, Mayet WJ, Matern S, Gartung C. Regulation of organic anion transporters in a new rat model of acute and chronic cholangitis resembling human primary sclerosing cholangitis. J. Hepatol. 36: 718-724 (2002). *

• Geier A, Dietrich CG, Trauner M, Gartung C. Extrahepatic cholestasis downregulates Oatp1 by TNF-alpha signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver. Liver Int. 27: 1056-1065 (2007). *

• Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, Trauner M, Wasmuth HE, Boraschi D, Balasubramaniyan N, Suchy FJ, Matern S, Gartung C. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G831-G841 (2005). *

• Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, Gartung C. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38: 345-354 (2003). *

• Geier A, Gartung C, Matern S. Regulation of hepatobiliary transporters in cholestatic liver disease. Med. Klin. (Munich) 99: 7-17 (2004).

• Geier A, Kim SK, Gerloff T, Dietrich CG, Lammert F, Karpen SJ, Stieger B, Meier PJ, Matern S, Gartung C. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J. Hepatol. 37: 198-205 (2002). *

• Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773: 283-308 (2007). *

• Gerloff T. Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn. Schmiedebergs Arch. Pharmacol. 369: 69-77 (2004). *

• Gerloff T, Geier A, Stieger B, Hagenbuch B, Meier PJ, Matern S, Gartung C. Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver. Gastroenterology 117: 1408-1415 (1999). *

• Geyer J, Godoy JR, Petzinger E. Identification of a sodium-dependent organic anion transporter from rat adrenal gland. Biochem. Biophys. Res. Commun. 316: 300-306 (2004). *

• Geyer J, Wilke T, Petzinger E. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn. Schmiedebergs. Arch. Pharmacol. 372: 413-431 (2006). *

• Gisler SM, Pribanic S, Bacic D, Forrer P, Gantenbein A, Sabourin LA, Tsuji A, Zhao ZS, Manser E, Biber J, Murer H. PDZK1: I. A major scaffolder in brush borders of proximal tubular cells. Kidney Int. 64: 1733-1745 (2003). *

• Gonzalez MA, Bernal CA, Mahieu S, Carrillo MC. The interactions between the chronic exposure to aluminum and liver regeneration on bile flow and organic anion transport in rats. Biol. Trace Elem. Res. 127: 164-176 (2009).

• Gonzalez MA, Roma MG, Bernal CA, Alvarez Mde L, Carrillo MC. Biliary secretory function in rats chronically intoxicated with aluminum. Toxicol. Sci. 79: 189-195 (2004). *

• Gradilone SA, Tietz PS, Splinter PL, Marinelli RA, LaRusso NF. Expression and subcellular localization of aquaporin water channels in the polarized hepatocyte cell line, WIF-B. BMC Physiol. 5: 13 (2005). *

• Graessler J, Graessler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E, Schroeder HE. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum. 54: 292-300 (2005). *

• Groves CE, Suhre WB, Cherrington NJ, Wright SH. Sex differences in the mRNA, protein and functional expression of Oat1, Oat3 and Oct2 in rabbit renal proximal tubules. J. Pharmacol. Exp. Ther. 316: 743-752 (2006). *

• Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80: 607-620 (2006). *

• Guo GL, Choudhuri S, Klaassen CD. Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. J. Pharmacol. Exp. Ther. 300: 206-212 (2002). *

• Guo GL, Staudinger J, Ogura K, Klaassen CD. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol. Pharmacol. 61: 832-839 (2002). *

• Hagenbuch B. Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract. Res. Clin. Endocrinol. Metab. 21: 209-221 (2007).

• Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38: 778-801 (2008). *

• Hagenbuch B, Meier PJ. Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Semin. Liver Dis. 16: 129-136 (1996).

• Hagenbuch B, Scharschmidt BF, Meier PJ. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem. J. 316: 901-904 (1996). *

• Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J. Hepatol. 34: 881-887 (2001). *

• Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J. Am. Soc. Nephrol. 18: 430-439 (2007). *

• Haimeur A, Conseil G, Deeley RG, Cole SP. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol. Pharmacol. 65: 1375-1385 (2004). *

• Hariparsad N, Carr BA, Evers R, Chu X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab. Dispos. 36: 1046-1055 (2008). *

• Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303: 273-281 (2002). *

• Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21: 1393-1403 (2001). *

• He Y, Zhang W, Tu J, Kirchheiner J, Chen Y, Guo D, Li Q, Li Z, Chen H, Hu D, Wang D, Zhou H. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab. Dispos. 36: 1453-1456 (2008). *

• Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a non-bile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314: 876-882 (2005). *

• Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34: 1229-1236 (2006). *

• Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J. Biol. Chem. 275: 2905-2910 (2000). *

• Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, Ohtsubo K, Sugiyama Y. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. 21: 742-748 (2004). *

• Hirouchi M, Suzuki H, Sugiyama Y. Treatment of hyperbilirubinemia in Eisai hyperbilirubinemic rat by transfecting human MRP2/ABCC2 gene. Pharm. Res. 22: 661-666 (2005). *

• Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806 (2006). *

• Hojo M, Sano N, Takikawa H. Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats. J. Gastroenterol. Hepatol. 18: 815-821 (2003). *

• Holzinger F, Schteingart CD, Ton-Nu HT, Eming SA, Monte MJ, Hagey LR, Hofmann AF. Fluorescent bile acid derivatives: relationship between chemical structure and hepatic and intestinal transport in the rat. Hepatology 26: 1263-1271 (1997). *

• Hong M, Tanaka K, Pan Z, Ma J, You G. Determination of the external loops and the cellular orientation of the N- and the C-termini of the human organic anion transporter hOAT1. Biochem. J. 401: 515-520 (2007). *

• Hong M, Zhou F, Lee K, You G. The putative transmembrane segment 7 of human organic anion transporter hOAT1 dictates transporter substrate binding and stability. J. Pharmacol. Exp. Ther. 320: 1209-1215 (2007). *

• Hong M, Zhou F, You G. Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1. J. Biol. Chem. 279: 31478-31482 (2004). *

• Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med. 30: 1440-1461 (2001).

• Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, Higuchi S, Otsubo K, Sugiyama Y. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol. Res. 30: 91-95 (2004).

• Ieiri I, Takane H, Hirota T, Otsubo K, Higuchi S. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin. Drug Metab. Toxicol. 2: 651-674 (2006).

• Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J. Biol. Chem. 277: 16860-16867 (2002). *

• Imaoka T, Kusuhara H, Adachi-Akahane S, Hasegawa M, Morita N, Endou H, Sugiyama Y. The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. J. Am. Soc. Nephrol. 15: 2012-2022 (2004). *

• Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos. 34: 1109-1115 (2006). *

• Ismair MG, Stanca C, Ha HR, Renner EL, Meier PJ, Kullak-Ublick GA. Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. Hepatol. Res. 26: 343-347 (2003).

• Itagaki S, Chiba M, Kobayashi M, Hirano T, Iseki K. Contribution of multidrug resistance-associated protein 2 to secretory intestinal transport of organic anions. Biol. Pharm. Bull. 31: 146-148 (2008). *

• Itagaki S, Shimamoto S, Hirano T, Iseki K, Sugawara M, Nishimura S, Fujimoto M, Kobayashi M, Miyazaki K. Comparison of urinary excretion of phenolsulfonphthalein in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Wistar rats: involvement of primary active organic anion transporter. J. Pharm. Pharm. Sci. 7: 227-234 (2004). *

• Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Hirano T, Iseki K. Comparison of the disposition behavior of organic anions in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Long-Evans Agouti rats. Drug Metab. Pharmacokinet. 19: 150-154 (2004). *

• Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K. Mechanism of active secretion of phenolsulfonphthalein in the liver via Mrp2 (abcc2), an organic anion transporter. Drug Metab. Pharmacokinet. 18: 238-244 (2004). *

• Itani T, Kobayashi Y, Kuroda M, Ma N, Mifuji R, Urawa N, Tanaka Y, Kaito M, Adachi Y. Transfecting the multidrug resistance protein 2 gene improves transcellular organic anion transport. Int. J. Mol. Med. 16: 821-825 (2005). *

• Ito K, Hoekstra D, van Ijzendoorn SC. Cholesterol but not association with detergent resistant membranes is necessary for the transport function of MRP2/ABCC2. FEBS Lett. 582: 4153-4157 (2008). *

• Ito K, Olsen SL, Qiu W, Deeley RG, Cole SP. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J. Biol. Chem. 276: 15616-15624 (2001). *

• Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22: 1559-1577 (2005). *

• Iwakiri T, Okumura M, Matsunaga N, Ichihara E, Shiotsuki S, Nagata M, Kumagai Y, Kai H, Arimori K. Hepatocyte growth factor increases uptake of estradiol 17beta-d-glucuronide and Oatp1 protein level in rat hepatocytes. Eur. J. Pharmacol. 580: 19-26 (2008). *

• Jacobsson JA, Haitina T, Lindblom J, Fredriksson R. Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family. Genomics 90: 595-609 (2007). *

• Jansen PL. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis. Baillieres Best Pract. Res. Clin. Gastroenterol. 14: 571-583 (2000).

• Jansen PL. Genetics of cholestasis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 37-40 (2006). *

• Jansen PL. Foreword: from classic bile physiology to cloned transporters. Semin. Liver Dis. 20: 245-250 (2000).

• Jensen LE, Wall AM, Cook M, Hoess K, Thorn CF, Whitehead AS, Mitchell LE. A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifida. Birth Defects Res. Part A. Clin. Mol. Teratol. 70: 396-399 (2004). *

• Jin MJ, Han HK. Interaction of zalcitabine with human organic anion transporter 1. Pharmazie 61: 491-492 (2006).

• Jindal C, Kumar S, Choudhari G, Goel H, Mittal B. Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease. Indian J. Med. Res. 129: 170-175 (2009).

• Johnson BM, Zhang P, Schuetz JD, Brouwer KL. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab. Dispos. 34: 556-562 (2006). *

• Jorgensen L, Van Beek J, Lund S, Schousboe A, Badolo L. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. Eur. J. Pharm. Sci. 30: 181-189 (2007). *

• Jung D, Elferink MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 27: 137-144 (2007). *

• Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J. Biol. Chem. 276: 37206-37214 (2001). *

• Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37: 622-631 (2003). *

• Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122: 1954-1966 (2002). *

• Jung SM, Lee WK, Kwak JO, Jung SY, Park J, Kim WY, Kim J, Cha SH. Identification of a novel murine organic anion transporter like protein 1 (OATLP1) expressed in the kidney. Exp. Mol. Med. 38: 485-493 (2006). *

• Kagawa T, Watanabe N, Sato M, Nakano A, Nishizaki Y, Hosoi K, Takashimizu S, Uchiyama J, Kimura M, Matsuzaki S. Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats. Biochem. Mol. Biol. Int. 44: 443-452 (1998).

• Kakizaki S, Yamazaki Y, Kosone T, Horigichi N, Sohara N, Sato K, Takagi H, Yoshinari K, Mori M. Gene expression profiles of drug-metabolizing enzymes and transporters with an overexpression of hepatocyte growth factor. Liver Int. 27: 109-119 (2007). *

• Kakizaki S, Yamazaki Y, Takizawa D, Negishi M. New insights on the xenobiotic-sensing nuclear receptors in liver diseases - CAR and PXR. Curr. Drug Metab. 9: 614-621 (2008).

• Kakyo M, Unno M, Tokui T, Nakagomi R, Nishio T, Iwasashi H, Nakai D, Seki M, Suzuki M, Naitoh T, Matsuno S, Yawo H, Abe T. Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. Gastroenterology 117: 770-775 (1999). *

• Kaler G, Truong DM, Sweeney DE, Logan DW, Nagle M, Wu W, Eraly SA, Nigam SK. Olfactory mucosa-expressed organic anion transporter, Oat6, manifests high affinity interactions with odorant organic anions. Biochem. Biophys. Res. Commun. 351: 872-876 (2006). *

• Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br. J. Clin. Pharmacol. 66: 818-825 (2008). *

• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158: 693-705 (2009). *

• Kamisako T, Gabazza EC, Ishihara T, Adachi Y. Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. J. Gastroenterol. Hepatol. 14: 405-412 (1999). *

• Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, Higuchi K, Tanaka Y, Gabazza EC, Adachi Y. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J. Gastroenterol. 35: 659-664 (2000). *

• Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin. Pharmacol. Ther. 79: 186-196 (2006). *

• Kauffmann HM, Keppler D, Gant TW, Schrenk D. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch. Toxicol. 72: 763-768 (1998). *

• Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 31: 1285-1295 (2000). *

• Kawase A, Tsunokuni Y, Iwaki M. Effects of alterations in CAR on bilirubin detoxification in mouse collagen-induced arthritis. Drug Metab. Dispos. 35: 256-261 (2007). *

• Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D, Kubitz R. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41: 1160-1172 (2005). *

• Kemp DC, Zamek-Gliszczynski MJ, Brouwer KL. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol. Sci. 83: 207-214 (2005). *

• Keppler D. Uptake and efflux transporters for conjugates in human hepatocytes. Methods Enzymol. 400: 531-542 (2005).

• Keppler D, Konig J. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J. 11: 509-516 (1997). *

• Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 378: 787-791 (1997).

• Keppler D, Leier I, Jedlitschky G, Mayer R, Buchler M. The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion. Adv. Enzyme Regul. 36: 17-29 (1996). *

• Keppler D, Rius M. The concept of basolateral efflux pumps of the hepatocyte. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 30-31 (2006). *

• Keppler D, Rius M, Nies AT. Bile salt efflux mediated by multidrug resistance protein MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 38. June 18-19 (2004). *

• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234: 4-33 (2006). *

• Kikuchi R, Kusuhara H, Hattori N, Shiota K, Kim I, Gonzalez FJ, Sugiyama Y. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation. Mol. Pharmacol. 70: 887-896 (2006). *

• Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest. 33 Suppl. 2: 1-5 (2003).

• Kipp H, Arias IM. Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin. Liver Dis. 20: 339-351 (2000).

• Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. J. Biol. Chem. 278: 17838-17844 (2003). *

• Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 36: 2014-2023 (2008). *

• Kitamura T, Jansen P, Hardenbrook C, Kamimoto Y, Gatmaitan Z, Arias IM. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. Proc. Natl. Acad. Sci. U.S.A. 87: 3557-3561 (1990). *

• Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24: 239-247 (2007). *

• Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci. 101: 186-196 (2008). *

• Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 6: 309-328 (2005).

• Kobayashi Y, Ohbayashi M, Kohyama N, Yamamoto T. Mouse organic anion transporter 2 and 3 (mOAT2/3[Slc22a7/8]) mediates the renal transport of bumetanide. Eur. J. Pharmacol. 524: 44-48 (2005).

• Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J. Pharm. Pharmacol. 57: 573-578 (2005).

• Kocher O, Comella N, Gilchrist A, Pal R, Tognazzi K, Brown LF, Knoll JH. PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab. Invest. 79: 1161-1170 (1999).

• Kocher O, Pal R, Roberts M, Cirovic C, Gilchrist A. Targeted disruption of the PDZK1 gene by homologous recombination. Mol. Cell. Biol. 23: 1175-1180 (2003). *

• Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369: 539-547 (2003). *

• Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 275: 23161-23168 (2000). *

• Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G156-G164 (2000). *

• Konig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29: 1156-1163 (1999). *

• Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn. Schmiedebergs. Arch. Pharmacol. 372: 432-443 (2006). *

• Koopen NR, Wolters H, Havinga R, Vonk RJ, Jansen PL, Muller M, Kuipers F. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 27: 537-545 (1998). *

• Kopplow K, Letschert K, Konig J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 68: 1031-1038 (2005). *

• Kotka M, Lieden A, Pettersson S, Trinchieri V, Masci A, D'Amato M. Solute carriers (SLC) in inflammatory bowel disease: a potential target of probiotics? J. Clin. Gastroenterol. 42 Suppl. 3: S133-S135 (2008).

• Kubo K, Sekine S, Saito M. Compensatory expression of MRP3 in the livers of MRP2-deficient EHBRs is promoted by DHA intake. Biosci. Biotechnol. Biochem. 73: 2432-2438 (2009).

• Kudo A, Kashiwagi S, Kajimura M, Yoshimura Y, Uchida K, Arii S, Suematsu M. Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver. Hepatology 39: 1099-1109 (2004). *

• Kullak-Ublick G. Pharmacogenetics. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 13 (2006). *

• Kullak-Ublick GA. Regulation of organic anion and drug transporters of the sinusoidal membrane. J. Hepatol. 31: 563-573 (1999). *

• Kullak-Ublick GA. Regulation of bile salt transporter genes by nuclear receptors. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 43. June 18-19 (2004). *

• Kullak-Ublick GA, Baretton GB, Oswald M, Renner EL, Paumgartner G, Beuers U. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol. Res. 23: 78-82 (2002).

• Kullak-Ublick GA, Becker MB. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev. 35: 305-317 (2003).

• Kullak-Ublick GA, Beuers U, Fahney C, Hagenbuch B, Meier PJ, Paumgartner G. Identification and functional characterization of the promoter region of the human organic anion transporting polypeptide gene. Hepatology 26: 991-997 (1997). *

• Kullak-Ublick GA, Beuers U, Meier PJ, Domdey H, Paumgartner G. Assignment of the human organic anion transporting polypeptide (OATP) gene to chromosome 12p12 by fluorescence in situ hybridization. J. Hepatol. 25: 985-987 (1996). *

• Kullak-Ublick GA, Beuers U, Paumgartner G. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23: 1053-1060 (1996). *

• Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120: 525-533 (2001). *

• Kullak-Ublick GA, Jung D, Hagenbuch B, Meier PJ. Organic anion transporting polypeptides, cholestasis, and nuclear receptors. Hepatology 35: 732-734 (2002). *

• Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin. Liver Dis. 20: 273-292 (2000). *

• Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126: 322-342 (2004). *

• Kurihara H, Sano N, Takikawa H. Biliary excretion of taurocholate, organic anions and vinblastine in rats with alpha-naphthylisothiocyanate-induced cholestasis. J. Gastroenterol. Hepatol. 20: 1069-1074 (2005). *

• Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. Neurorx. 2: 73-85 (2005).

• Kwak JO, Kim HW, Oh KJ, Ko CB, Park H, Cha SH. Characterization of mouse organic anion transporter 5 as a renal steroid sulfate transporter. J. Steroid Biochem. Mol. Biol. 97: 369-375 (2005).

• Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).

• Lash LH, Putt DA, Cai H. Membrane transport function in primary cultures of human proximal tubular cells. Toxicology 228: 200-218 (2006). *

• Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, Deray G. Renal tubular drug transporters. Nephron. Physiol. 103: p97-p106 (2006).

• Lazaridis KN, LaRusso NF. Bile formation: do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology 37: 218-220 (2003). *

• Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the pro-inflammatory cytokine interleukin-1beta. Drug Metab. Dispos. 36: 217-222 (2008). *

• Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the pro-inflammatory cytokines TNF-alpha or IL-6. Drug Metab. Dispos. 37: 685-693 (2009). *

• Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 118: 163-172 (2000). *

• Lee YM, Cui Y, Konig J, Risch A, Jager B, Drings P, Bartsch H, Keppler D, Nies AT. Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 14: 213-223 (2004).

• Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167: 3-23 (2001). *

• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204: 216-237 (2005). *

• Leslie EM, Haimeur A, Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 279: 32700-32708 (2004). *

• Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14: 441-452 (2004).

• Letschert K, Komatsu M, Hummel-Eisenbeiss J, Keppler D. Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2 (MRP2). J. Pharmacol. Exp. Ther. 313: 549-556 (2005). *

• Li GX, Pei QL, Gao Y, Liu KM, Nie JS, Han G, Qiu YL, Zhang WP. Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats. Exp. Toxicol. Pathol. 58: 447-453 (2007). *

• Li N, Choudhuri S, Cherrington NJ, Klaassen CD. Down-regulation of mouse organic anion-transporting polypeptide 4 (Oatp4; Oatp1b2; Slc21a10) mRNA by lipopolysaccharide through the Toll-like receptor 4 (TLR4). Drug Metab. Dispos. 32: 1265-1271 (2004). *

• Li N, Hartley DP, Cherrington NJ, Klaassen CD. Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. J. Pharmacol. Exp. Ther. 301: 551-560 (2002). *

• Li N, Klaassen CD. Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (oatp4; oatplb2; slc21a10) by lipopolysaccharide. Mol. Pharmacol. 66: 694-701 (2004). *

• Li N, Klaassen CD. Lipopolysaccharide-induced down-regulation of organic anion transporting polypeptide 4 (Oatp4; Slc21a10) is independent of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, or inducible nitric oxide synthase. Toxicol. Sci. 83: 197-203 (2005). *

• Lin Z, Fontaine J, Watchko JF. Coexpression of gene polymorphisms involved in bilirubin production and metabolism. Pediatrics 122: e156-e162 (2008). *

• Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 318: 395-402 (2006). *

• Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, Brouwer KL. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol. 277: G12-G21 (1999). *

• Ljubojevic M, Balen D, Breljak D, Kusan M, Anzai N, Bahn A, Burckhardt G, Sabolic I. Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones. Am. J. Physiol. Renal Physiol. 292: F361-F372 (2007). *

• Lomri N, Fitz JG, Scharschmidt BF. Hepatocellular transport: role of ATP-binding cassette proteins. Semin. Liver Dis. 16: 201-210 (1996).

• Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab. Dispos. 26: 1217-1222 (1998). *

• Lu H, Choudhuri S, Ogura K, Csanaky IL, Lei X, Cheng X, Song PZ, Klaassen CD. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol. Sci. 103: 35-45 (2008). *

• Lungkaphin A, Lewchalermwongse B, Chatsudthipong V. Relative contribution of OAT1 and OAT3 transport activities in isolated perfused rabbit renal proximal tubules. Biochim. Biophys. Acta 1758: 789-795 (2006). *

• Machuca C, Rodriguez A, Herrera M, Silva S, Ponte-Sucre A. Leishmania amazonensis: metabolic adaptations induced by resistance to an ABC transporter blocker. Exp. Parasitol. 114: 1-9 (2006). *

• Madejczyk MS, Aremu DA, Simmons-Willis TA, Clarkson TW, Ballatori N. Accelerated urinary excretion of methylmercury following administration of its antidote N-acetylcysteine requires Mrp2/Abcc2, the apical multidrug resistance-associated protein. J. Pharmacol. Exp. Ther. 322: 378-384 (2007). *

• Maeda K, Kambara M, Tian Y, Hofmann AF, Sugiyama Y. Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). Mol. Pharm. 3: 70-77 (2006). *

• Maeda T, Hirayama M, Higashi R, Sato M, Tamai I. Characterization of human OATP2B1 (SLCO2B1) gene promoter regulation. Pharm. Res. 23: 513-520 (2006). *

• Maeda T, Miyata M, Yotsumoto T, Kobayashi D, Nozawa T, Toyama K, Gonzalez FJ, Yamazoe Y, Tamai I. Regulation of drug transporters by the farnesoid X receptor in mice. Mol. Pharm. 1: 281-289 (2004).

• Maeda T, Takahashi K, Ohtsu N, Oguma T, Ohnishi T, Atsumi R, Tamai I. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharm. 4: 85-94 (2007). *

• Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. Human organic anion transporter 1B1 (OATP1B1/OATP-C) and 1B3 (OATP1B3/OATP-8) function as bidirectional carriers and do not mediate GSH-bile acid co-transport. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G271-G278 (2007). *

• Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem. Pharmacol. 72: 512-522 (2006). *

• Makowski P, Pikula S. Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol. J. Pharmacol. 49: 387-394 (1997).

• Mansour NM, Sawhney M, Tamang DG, Vogl C, Saier MH Jr. The bile/arsenite/riboflavin transporter (BART) superfamily. FEBS J. 274: 612-629 (2007). *

• Marin JJ, Macias RI, Briz O, Perez MJ, Serrano MA. Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Ann. Hepatol. 4: 70-76 (2005).

• Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485 (2005). *

• Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549-560 (2005). *

• Marumo T, Fukusato T, Takikawa H. Biliary excretion of bile acids and organic anions in rats with dichloroethylene-induced bile canalicular injury. J. Gastroenterol. 39: 981-987 (2004). *

• Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 21: 1769-1780 (2007). *

• Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5: 273-282 (2004).

• Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 73: 1474-1483 (2008). *

• Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double transfected MDCKII cells expressing human OATP1B1/MRP2, OATP1B1/MDR1 and OATP1B1/BCRP. J. Pharmacol. Exp. Ther. 314: 1059-1067 (2005). *

• Meier PJ. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am. J. Physiol. 269: G801-G812 (1995).

• Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26: 1667-1677 (1997). *

• Meier PJ, Stieger B. Bile salt transporters. Annu. Rev. Physiol. 64: 635-661 (2002). *

• Meier-Abt F, Faulstich H, Hagenbuch B. Identification of phalloidin uptake systems of rat and human liver. Biochim. Biophys. Acta 1664: 64-69 (2004). *

• Meier-Abt F, Hammam-Hanni A, Stieger B, Ballatori N, Boyer JL. The organic anion transport polypeptide 1d1 (Oatp1d1) mediates hepatocellular uptake of phalloidin and microcystin into skate liver. Toxicol. Appl. Pharmacol. 218: 274-279 (2007). *

• Meier-Abt PJ. Transport and metabolic functions. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 21-22. October 20 - 21 (2003). *

• Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. New molecular features of cholestatic diseases of the liver. Rev. Invest. Clin. 55: 546-556 (2003).

• Mendoza ME, Monte MJ, Serrano MA, Pastor-Anglada M, Stieger B, Meier PJ, Medarde M, Marin JJ. Physiological characteristics of allo-cholic acid. J. Lipid Res. 44: 84-92 (2003). *

• Meng LJ, Wang P, Wolkoff AW, Kim RB, Tirona RG, Hofmann AF, Pang KS. Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. Hepatology 35: 1031-1040 (2002). *

• Mesotten D, Van den Berghe G, Liddle C, Coulter S, McDougall F, Baxter RC, Delhanty PJ. Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology 144: 4008-4017 (2003). *

• Meyer Zu Schwabedissen HE, Kim RB. Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol. Pharm. 6: 1644-1661 (2009). *

• Meyer Zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res. 68: 9338-9347 (2008). *

• Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277: 43058-43063 (2002). *

• Mikamo E, Harada S, Nishikawa J, Nishihara T. Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol. Appl. Pharmacol. 193: 66-72 (2003). *

• Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 66: 535-542 (2006). *

• Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet. 19: 171-179 (2004). *

• Milkiewicz P, Chilton AP, Hubscher SG, Elias E. Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2). Gut 52: 300-303 (2003). *

• Mills CO, Milkiewicz P, Muller M, Roma MG, Havinga R, Coleman R, Kuipers F, Jansen PL, Elias E. Different pathways of canalicular secretion of sulfated and non-sulfated fluorescent bile acids: a study in isolated hepatocyte couplets and TR- rats. J. Hepatol. 31: 678-684 (1999). *

• Mills CO, Milkiewicz P, Saraswat V, Elias E. Cholyllysyl fluroscein and related lysyl fluorescein conjugated bile acid analogues. Yale J. Biol. Med. 70: 447-457 (1997).

• Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63: 1161-1169 (2007).

• Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin HJ, Jutabha P, Hirata T, He X, Nonoguchi H, Tomita K, Kanai Y, Endou H. Modulation of renal apical organic aniontransporter 4 function by two PDZ domain-containing proteins. J. Am. Soc. Nephrol. 16: 3498-3506 (2005). *

• Mizuno N, Takahashi T, Iwase Y, Kusuhara H, Niwa T, Sugiyama Y. Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab. Dispos. 35: 1429-1434 (2007). *

• Monks NR, Liu S, Xu Y, Yu H, Bendelow AS, Moscow JA. Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol. Cancer Ther. 6: 587-598 (2007). *

• Mori S, Ohtsuki S, Takanaga H, Kikkawa T, Kang YS, Terasaki T. Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J. Neurochem. 90: 931-941 (2004). *

• Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 14: 7068-7074 (2008). *

• Mudaliar A, Eraly SA. Comparison of gene expression in the kidneys of male and female mice using the DNA microarray Mgu74Av2. Ethn. Dis. 15: S4,S82-S83 (2005).

• Muller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am. J. Physiol. 272: G1285-G1303 (1997).

• Muller M, Roelofsen H, Jansen PL. Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Semin. Liver Dis. 16: 211-220 (1996).

• Muller O, Schalla C, Scheibner J, Stange EF, Fuchs M. Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice. Biochem. J. 361: 673-679 (2002). *

• Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 37: 416-426 (2007). *

• Negis Y, Meydani M, Zingg JM, Azzi A. Molecular mechanism of alpha-tocopheryl-phosphate transport across the cell membrane. Biochem. Biophys. Res. Commun. 359: 348-353 (2007). *

• Newton DJ, Wang RW, Evans DC. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR(-) and EHBR rats. Life Sci. 77: 1106-1115 (2005). *

• Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet. Genomics 16: 565-568 (2006).

• Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80: 356-366 (2006). *

• Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429-440 (2004).

• Nilwarangkoon S, Anzai N, Shiraya K, Yu E, Islam R, Cha SH, Onozato ML, Miura D, Jutabha P, Tojo A, Kanai Y, Endou H. Role of mouse organic anion transporter 3 (mOat3) as a basolateral prostaglandin E(2) transport pathway. J. Pharmacol. Sci. 103: 48-55 (2007). *

• Notenboom S, Wouterse AC, Peters B, Kuik LH, Heemskerk S, Russel FG, Masereeuw R. Increased apical insertion of the multidrug resistance protein 2 (MRP2/ABCC2) in renal proximal tubules following gentamicin exposure. J. Pharmacol. Exp. Ther. 318: 1194-1202 (2006). *

• Nozawa T, Sugiura S, Hashino Y, Tsuji A, Tamai I. Role of anion exchange transporter PAT1 (SLC26A6) in intestinal absorption of organic anions. J. Drug Target. 12: 97-104 (2004).

• Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab. Dispos. 32: 291-294 (2004). *

• Ogasawara K, Terada T, Asaka JI, Katsura T, Inui KI. Human organic anion transporter 3 gene is regulated constitutively and inducibly via a cAMP responsive element. J. Pharmacol. Exp. Ther. 319: 317-322 (2006). *

• Ogasawara K, Terada T, Asaka JI, Katsura T, Inui KI. Hepatocyte nuclear factor-4alpha regulates the human organic anion transporter 1 gene in the kidney. Am. J. Physiol. Renal Physiol. 292: F1819-F1826 (2007). *

• Ogasawara K, Terada T, Motohashi H, Asaka JI, Aoki M, Katsura T, Kamba T, Ogawa O, Inui KI. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J. Hum. Genet. 53: 607-614 (2008).

• Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G438-G446 (2000). *

• Ohtsuka H, Abe T, Onogawa T, Kondo N, Sato T, Oshio H, Mizutamari H, Mikkaichi T, Oikawa M, Rikiyama T, Katayose Y, Unno M. Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J. Gastroenterol. 41: 369-377 (2006). *

• Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T. Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J. Pharmacol. Exp. Ther. 309: 1273-1281 (2004). *

• Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol. 14: 136-142 (2009).

• Ortiz DF, Li S, Iyer R, Zhang X, Novikoff P, Arias IM. MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am. J. Physiol. 276: G1493-G1500 (1999). *

• Ortiz DF, Moseley J, Calderon G, Swift AL, Li S, Arias IM. Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells. J. Biol. Chem. 279: 32761-32770 (2004). *

• Oshima H, Kon J, Ooe H, Hirata K, Mitaka T. Functional expression of organic anion transporters in hepatic organoids reconstructed by rat small hepatocytes. J. Cell. Biochem. 104: 68-81 (2008). *

• Oshio H, Abe T, Onogawa T, Ohtsuka H, Sato T, Ii T, Fukase K, Muto M, Katayose Y, Oikawa M, Rikiyama T, Egawa S, Unno M. Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. J. Gastroenterol. 43: 538-549 (2008). *

• Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 21: 247-253 (2001). *

• Oude Elferink RP. Cholestasis. Gut 52 Suppl. 2: ii42-ii48 (2003). *

• Oude Elferink RP, Tytgat GN, Groen AK. Hepatic canalicular membrane 1: the role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB J. 11: 19-28 (1997). *

• Pan G, Giri N, Elmquist WF. Abcg2/Bcrp1 mediates the polarized transport of anti-retroviral nucleosides abacavir and zidovudine. Drug Metab. Dispos. 35: 1165-1173 (2007). *

• Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62: 409-415 (2006). *

• Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet. Genomics 18: 921-926 (2008).

• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16: 873-879 (2006).

• Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ, Stieger B, Brouwer KL. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol. Pharmacol. 64: 154-159 (2003). *

• Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271: 1126-1128 (1996). *

• Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, Oude Elferink RP. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25: 1539-1542 (1997). *

• Paulusma CC, van Geer MA, Evers R, Heijn M, Ottenhoff R, Borst P, Oude Elferink RP. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem. J. 338: 393-401 (1999). *

• Perry JL, Dembla-Rajpal N, Hall LA, Pritchard JB. A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport. J. Biol. Chem. 281: 38071-38079 (2006). *

• Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, Marquet P. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther. 87: 100-108 (2010). *

• Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol. Endocrinol. 16: 2283-2296 (2002). *

• Planchamp C, Hadengue A, Stieger B, Bourquin J, Vonlaufen A, Frossard JL, Quadri R, Becker CD, Pastor CM. Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol. Pharmacol. 71: 1089-1097 (2007). *

• Planchamp C, Montet X, Frossard JL, Quadri R, Stieger B, Meier PJ, Ivancevic MK, Vallee JP, Terrier F, Pastor CM. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest. Radiol. 40: 187-194 (2005).

• Popowski K, Eloranta JJ, Saborowski M, Fried M, Meier PJ, Kullak-Ublick GA. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol. Pharmacol. 67: 1629-1638 (2005). *

• Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ. Human vascular smooth muscle cells express a urate transporter. J. Am. Soc. Nephrol. 17: 1791-1795 (2006). *

• Puffer AB, Meschter EE, Musch MW, Goldstein L. Membrane trafficking factors are involved in the hypotonic activation of the taurine channel in the little skate (Raja erinacea) red blood cell. J. Exp. Zoolog. A. Comp. Exp. Biol. 305: 594-601 (2006). *

• Purucker E, Marschall HU, Geier A, Gartung C, Matern S. Increase in renal glutathione in cholestatic liver disease is due to a direct effect of bile acids. Am. J. Physiol. Renal Physiol. 283: F1281-F1289 (2002). *

• Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 80: 468-476 (2006). *

• Ravna AW, Sylte I, Sager G. Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theor. Biol. Med. Model. 4: 33 (2007). *

• Reinehr R, Becker S, Keitel V, Eberle A, Grether-Beck S, Haussinger D. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 129: 2009-2031 (2005). *

• Rengelshausen J, Lindenmaier H, Cihlar T, Walter-Sack I, Haefeli WE, Weiss J. Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine. Biochem. Biophys. Res. Commun. 320: 90-94 (2004). *

• Rippin SJ, Hagenbuch B, Meier PJ, Stieger B. Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology 33: 776-782 (2001). *

• Ritter CA, Jedlitschky G, Meyer zu Schwabedissen H, Grube M, Kock K, Kroemer HK. Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab. Rev. 37: 253-278 (2005). *

• Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G640-G649 (2006). *

• Rius M, Thon WF, Keppler D, Nies AT. Prostanoid transport by multidrug resistance protein 4 (mrp4/abcc4) localized in tissues of the human urogenital tract. J. Urol. 174: 2409-2414 (2005).

• Rizwan AN, Krick W, Burckhardt G. The chloride dependence of the human organic anion transporter 1 (hOAT1) is blunted by mutation of a single amino acid. J. Biol. Chem. 282: 13402-13409 (2007). *

• Roelofsen H, Hooiveld GJ, Koning H, Havinga R, Jansen PL, Muller M. Glutathione S-conjugate transport in hepatocytes entering the cell cycle is preserved by a switch in expression from the apical MRP2 to the basolateral MRP1 transporting protein. J. Cell Sci. 112: 1395-1404 (1999). *

• Roelofsen H, Muller M, Jansen PL. Regulation of organic anion transport in the liver. Yale J. Biol. Med. 70: 435-445 (1997).

• Roelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H, Jansen PL, Muller M. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112: 511-521 (1997). *

• Rost D, Herrmann T, Sauer P, Schmidts HL, Stieger B, Meier PJ, Stremmel W, Stiehl A. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate. Hepatology 38: 187-195 (2003). *

• Rost D, Kopplow K, Gehrke S, Mueller S, Friess H, Ittrich C, Mayer D, Stiehl A. Gender-specific expression of liver organic anion transporters in rat. Eur. J. Clin. Invest. 35: 635-643 (2005).

• Rost D, Kopplow K, Gehrke S, Stiehl A, Mayer D. Gender-specific expression of liver organic anion transporters. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 39. June 18-19 (2004). *

• Rothnie A, Callaghan R, Deeley RG, Cole SP. Role of GSH in estrone sulphate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J. Biol. Chem. 281: 13906-13914 (2006). *

• Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *

• Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab. Dispos. 34: 1423-1431 (2006). *

• Sakamoto S, Kusuhara H, Miyata K, Shimaoka H, Kanazu T, Matsuo Y, Nomura K, Okamura N, Hara S, Horie K, Baba T, Sugiyama Y. Glucuronidation converting S-8921 to a potent ASBT inhibitor, resulting in a hypocholesterolemic action. J. Pharmacol. Exp. Ther. 322: 610-618 (2007). *

• Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch. Komplementarmed. 14: 70-80 (2007).

• Sano K, Chijiiwa K, Kai M, Hidaka Y, Kanemaru M. Differential expression of organic anion transporters in rats subjected to 70% or 90% hepatectomy. Hepatogastroenterology 56: 176-180 (2009).

• Sauer P, Stiehl A, Fitscher BA, Riedel HD, Benz C, Kloters-Plachky P, Stengelin S, Stremmel W, Kramer W. Downregulation of ileal bile acid absorption in bile-duct-ligated rats. J. Hepatol. 33: 2-8 (2000). *

• Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49: 1228-1235 (2009). *

• Schnabolk GW, Youngblood GL, Sweet DH. Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). Am. J. Physiol. Renal Physiol. 291: F314-F321 (2006). *

• Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dorje F, Fromm MF, Konig J. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35: 779-786 (2007). *

• Seithel A, Glaeser H, Fromm MF, Konig J. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin. Drug Metab. Toxicol. 4: 51-64 (2008).

• Serrano MA, Macias RI, Vallejo M, Briz O, Bravo A, Pascual MJ, St-Pierre MV, Stieger B, Meier PJ, Marin JJ. Effect of ursodeoxycholic acid on the impairment induced by maternal cholestasis in the rat placenta-maternal liver tandem excretory pathway. J. Pharmacol. Exp. Ther. 305: 515-524 (2003). *

• Servais A, Lechat P, Zahr N, Urien S, Aymard G, Jaudon MC, Deray G, Isnard Bagnis C. Tubular transporters OAT1 and MRP2 and clearance of adefovir. Nephrol. Ther. 1: 296-300 (2005).

• Seward DJ, Koh AS, Boyer JL, Ballatori N. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J. Biol. Chem. 278: 27473-27482 (2003). *

• Shaffer EA. Cholestasis: the ABCs of cellular mechanisms for impaired bile secretion - transporters and genes. Can. J. Gastroenterol. 16: 380-389 (2002). *

• Shibayama Y, Takeda Y, Yamada K. Effect of methotrexate treatment on expression levels of organic anion transporter polypeptide 2, P-glycoprotein and bile salt export pump in rats. Biol. Pharm. Bull. 32: 493-496 (2009). *

• Shibayama Y, Ushinohama K, Ikeda R, Yoshikawa Y, Motoya T, Takeda Y, Yamada K. Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci. 97: 1260-1266 (2006). *

• Shim WS, Choi MK, Kim IW, Kwon TS, Song IS, Han L, Kim DD, Chung SJ, Shim CK. Decreased secretory transport of a quarternary ammonium, TBuMA, across LLC-PK1 cells by the anionic kidney extract. Arch. Pharm. Res. 31: 671-677 (2008). *

• Shin HJ, Anzai N, Enomoto A, He X, Kim do K, Endou H, Kanai Y. Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate. Hepatology 45: 1046-1055 (2007). *

• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27: 425-446 (2006). *

• Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45: 689-723 (2005). *

• Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, Ikegami T, Tanaka N, Akita H, Ito K, Suzuki H, Sugiyama Y. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology 39: 167-178 (2004). *

• Sidler Pfandler MA, Hochli M, Inderbitzin D, Meier PJ, Stieger B. Small hepatocytes in culture develop polarized transporter expression and differentiation. J. Cell. Sci. 117: 4077-4087 (2004). *

• Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, Geier A. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem. Biophys. Res. Commun. 322: 232-238 (2004). *

• Silva VM, Hennig GE, Manautou JE. Cholestasis induced by model organic anions protects from acetaminophen hepatotoxicity in male CD-1 mice. Toxicol. Lett. 160: 204-211 (2005). *

• Simon FR, Iwahashi M, Hu LJ, Qadri I, Arias IM, Ortiz D, Dahl R, Sutherland E. Hormonal regulation of hepatic multidrug resistance-associated protein 2 (Abcc2) primarily involves the pattern of growth hormone secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G595-G608 (2006). *

• Situ D, Haimeur A, Conseil G, Sparks KE, Zhang D, Deeley RG, Cole SP. Mutational analysis of ionizable residues proximal to the cytoplasmic Interface of membrane spanning domain 3 of the multidrug resistance protein, MRP1 (ABCC1). Glutamate1204 is important for both the expression and catalytic activity of the transporter. J. Biol. Chem. 279: 38871-38880 (2004). *

• Smeets PH, van Aubel RA, Wouterse AC, van den Heuvel JJ, Russel FG. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol. 15: 2828-2835 (2004). *

• Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 4: 815-818 (2005). *

• Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol. 1: 429-445 (2005).

• Splinter PL, Lazaridis KN, Dawson PA, LaRrusso NF. Cloning and expression of SLC10A4, a putative organic anion transport protein. World J. Gastroenterol. 12: 6797-6805 (2006). *

• St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ. Transport of bile acids in hepatic and non-hepatic tissues. J. Exp. Biol. 204: 1673-1686 (2001). *

• St-Pierre MV, Stallmach T, Freimoser Grundschober A, Dufour JF, Serrano MA, Marin JJ, Sugiyama Y, Meier PJ. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287: R1505-R1516 (2004). *

• Stahl S, Davies MR, Cook DI, Graham MJ. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. Xenobiotica 38: 725-777 (2008). *

• Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos. 29: 1467-1472 (2001). *

• Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 98: 3369-3374 (2001). *

• Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U.S.A. 102: 2063-2068 (2005). *

• Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118: 422-430 (2000). *

• Stojic J, Stoehr H, Weber BH. Three novel ABCC5 splice variants in human retina and their role as regulators of ABCC5 gene expression. BMC Mol. Biol. 8: 42 (2007). *

• Suchy FJ, Sippel CJ, Ananthanarayanan M. Bile acid transport across the hepatocyte canalicular membrane. FASEB J. 11: 199-205 (1997). *

• Sugiyama Y, Mita S, Maeda K, Suzuki H. Analysis of vectorial transport of bile salts using human NTCP and human BSEP doubly expressing cells: comparative studies with rat Ntcp and rat Bsep. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 40. June 18-19 (2004). *

• Sun AQ, Balasubramaniyan N, Chen H, Shahid M, Suchy FJ. Identification of functionally relevant residues of the rat ileal apical sodium dependent bile acid cotransporter (rASBT). J. Biol. Chem. 281: 16410-16418 (2006). *

• Sun AQ, Balasubramaniyan N, Liu CJ, Shahid M, Suchy FJ. Association of the 16 kDa subunit c of vacuolar proton pump with the ileal Na+-dependent bile acid transporter: protein-protein interaction and intracellular trafficking. J. Biol. Chem. 279: 16295-16300 (2004). *

• Sun AQ, Ponamgi VM, Boyer JL, Suchy FJ. Membrane trafficking of the human organic anion-transporting polypeptide C (hOATPC). Pharm. Res. 25: 463-474 (2008). *

• Suzuki C, Sano N, Takikawa H. Effect of dexamethasone on biliary excretion of bile acids and organic anions in rats. Hepatol. Res. 25: 48-54 (2003). *

• Suzuki H. Analysis of xenobiotic detoxification system mediated by efflux transporters. Yakugaku Zasshi 119: 822-834 (1999).

• Suzuki H, Sugiyama Y. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. Semin. Liver Dis. 20: 251-263 (2000).

• Tachizawa H, Sano N, Takikawa H. Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats. J. Gastroenterol. Hepatol. 19: 1016-1022 (2004). *

• Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y. Inhibition of OAT3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab. Dispos. 34: 743-747 (2006). *

• Takikawa H. Organic anion carriers. Nippon Rinsho 54: 646-651 (1996).

• Takikawa H. Hepatobiliary transport of bile acids and organic anions. J. Hepatobiliary Pancreat. Surg. 9: 443-447 (2002).

• Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273: 251-260 (2000). *

• Tanaka K, Xu W, Zhou F, You G. Role of glycosylation in the organic anion transporter OAT1. J. Biol. Chem. 279: 14961-14966 (2004). *

• Tanaka K, Zhou F, Kuze K, You G. Cysteine residues in the organic anion transporter mOAT1. Biochem. J. 380: 283-287 (2004). *

• Tanaka Y, Chen C, Maher JM, Klaassen CD. Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. Transplantation 82: 258-266 (2006).

• Tanaka Y, Yoshikawa M, Kobayashi Y, Kuroda M, Kaito M, Shiroi A, Yamao J, Fukui H, Ishizaka S, Adachi Y. Expressions of hepatobiliary organic anion transporters and bilirubin-conjugating enzyme in differentiating embryonic stem cells. Biochem. Biophys. Res. Commun. 309: 324-330 (2003). *

• The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359: 789-799 (2008). *

• Thwaites DT, Anderson CM. H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp. Physiol. 92: 603-619 (2007). *

• Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky M, Kruh G, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab. Dispos. 36: 911-915 (2008). *

• Tian X, Zamek-Gliszczynski MJ, Zhang P, Brouwer KL. Modulation of multidrug resistance-associated protein 2 (mrp2) and mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol. Pharmacol. 66: 1004-1010 (2004). *

• Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304: 223-228 (2003). *

• Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, Adachi Y, Sakisaka S, Kuwano M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64: 739-746 (1999). *

• Tohyama K, Kusuhara H, Sugiyama Y. Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology 145: 4384-4391 (2004). *

• Toms TE, Smith JP, Panoulas VF, Douglas KM, Saratzis AN, Kitas GD. Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients. Musculoskeletal Care Jul 29 [Epub ahead of print] (2009).

• Tong Y, Zhang R, Ngo SN, Davey AK. Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. Clin. Exp. Pharmacol. Physiol. 33: 685-689 (2006). *

• Torres AM. Renal elimination of organic anions in cholestasis. World J. Gastroenterol. 14: 6616-6621 (2008). *

• Trauner M. Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations. Yale J. Biol. Med. 70: 365-378 (1997). *

• Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Hepatology 40: 260-263 (2004). *

• Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83: 633-671 (2003). *

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *

• Trauner M, Fickert P, Stauber RE. Hepatocellular bile salt transport: lessons from cholestasis. Can. J. Gastroenterol. 14 Suppl. D: 99D-104D (2000).

• Trauner M, Fickert P, Stauber RE. New molecular aspects of cholestatic liver diseases. Z. Gastroenterol. 37: 639-647 (1999).

• Trauner M, Fickert P, Wagner M, Zollner G. Adaptive hepatobiliary transporter regulation by ursodeoxycholic acid. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 48-49. June 18-19 (2004). *

• Trauner M, Fickert P, Zollner G. Genetic disorders and molecular mechanisms in cholestatic liver disease - a clinical approach. Semin. Gastrointest. Dis. 12: 66-88 (2001).

• Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27: 5972-5978 (2009).

• Tsuda-Tsukimoto M, Maeda T, Iwanaga T, Kume T, Tamai I. Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm. Res. 23: 2646-2656 (2006). *

• Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab. Pharmacokinet. 21: 165-169 (2006). *

• Turncliff RZ, Meier PJ, Brouwer KL. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 32: 834-839 (2004). *

• Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm. Res. 21: 976-981 (2004).

• Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24: 811-815 (2007). *

• van Aubel RA, Smeets PH, Van Den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal Physiol. 288: F327-F333 (2005). *

• van der Deure WM, Friesema EC, de Jong FJ, de Rijke YB, de Jong FH, Uitterlinden AG, Breteler MM, Peeters RP, Visser TJ. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology 149: 4695-4701 (2008). *

• van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK. Drug uptake systems in liver and kidney. Curr. Drug Metab. 4: 185-211 (2003).

• Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J. Hepatol. 40: 212-218 (2004). *

• Vicens M, Medarde M, Macias RI, Larena MG, Villafaina A, Serrano MA, Marin JJ. Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorg. Med. Chem. 15: 2359-2367 (2007). *

• Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, Muller M. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28: 1637-1644 (1998). *

• Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, Yoshida I, Kimura A, Sakisaka S, Adachi Y, Kuwano M. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. 7: 203-207 (1998). *

• Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42: 420-430 (2005). *

• Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 51: 565-580 (2009). *

• Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42: 1331-1357 (2003).

• Wang P, Wang JJ, Xiao Y, Murray JW, Novikoff PM, Angeletti RH, Orr GA, Lan D, Silver DL, Wolkoff AW. Interaction with PDZK1 is required for expression of organic anion transporting protein 1A1 on the hepatocyte surface. J. Biol. Chem. 280: 30143-30149 (2005). *

• Wang PY, Boccanfuso M, Lemay AM, Devries H, Sui J, She Y, Hill CE. Sex-specific extraction of organic anions by the rat liver. Life Sci. 82: 436-443 (2008). *

• Wang W, Seward DJ, Li L, Boyer JL, Ballatori N. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc. Natl. Acad. Sci. U.S.A. 98: 9431-9436 (2001). *

• Wang W, Soroka CJ, Mennone A, Rahner C, Harry K, Pypaert M, Boyer JL. Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes. Gastroenterology 131: 878-884 (2006). *

• Wolkoff AW. Hepatocellular sinusoidal membrane organic anion transport and transporters. Semin. Liver Dis. 16: 121-127 (1996).

• Wolters H, Elzinga BM, Baller JF, Boverhof R, Schwarz M, Stieger B, Verkade HJ, Kuipers F. Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J. Hepatol. 37: 556-563 (2002). *

• Wong H, Lehman-McKeeman LD, Grubb MF, Grossman SJ, Bhaskaran VM, Solon EG, Shen HS, Gerson RJ, Car BD, Zhao B, Gemzik B. Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 84: 232-242 (2005). *

• Wood M, Ananthanarayanan M, Jones B, Wooton-Kee R, Hoffman T, Suchy FJ, Vore M. Hormonal regulation of hepatic organic anion transporting polypeptides. Mol. Pharmacol. 68: 218-225 (2005). *

• Wright SH, Dantzler WH. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 84: 987-1049 (2004). *

• Wu P, Oleschuk CJ, Mao Q, Keller BO, Deeley RG, Cole SP. Analysis of human multidrug resistance protein 1 (ABCC1) by matrix-assisted laser desorption ionization/time of flight mass spectrometry: towards identification of leukotriene C4 binding sites. Mol. Pharmacol. 68: 1455-1465 (2005). *

• Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet. Genomics 19: 447-457 (2009).

• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28: 249-268 (2005).

• Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK. Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. 68: 1491-1499 (2005). *

• Xu G, Chen X, Wu D, Shi S, Wang J, Ding R, Hong Q, Feng Z, Lin S, Lu Y. Development of high-specificity antibodies against renal urate transporters using genetic immunization. J. Biochem. Mol. Biol. 39: 696-702 (2006). *

• Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, Liu ZQ, Wang D, Huang YF, Zhou HH, Sun ZQ. Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol. Sin. 28: 1693-1697 (2007).

• Xu W, Tanaka K, Sun AQ, You G. The functional role of the C terminus of human organic anion transporter hOAT1. J. Biol. Chem. 281: 31178-31183 (2006). *

• Yabuuchi H, Tamai I, Sai Y, Tsuji A. Possible role of anion exchanger AE2 as the intestinal monocarboxylic acid/anion antiporter. Pharm. Res. 15: 411-416 (1998). *

• Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H, Sato M, Matsuura M, Saga T, Unno M, Abe T, Mano N, Hishinuma T, Goto J. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J. Lipid Res. 47: 1196-1202 (2006). *

• Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos. 34: 1247-1254 (2006). *

• Yamashita F, Ohtani H, Koyabu N, Ushigome F, Satoh H, Murakami H, Uchiumi T, Nakamura T, Kuwano M, Tsujimoto M, Sawada Y. Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J. Pharm. Pharmacol. 58: 1499-1505 (2006).

• Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35: 737-753 (2005). *

• Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J. Alzheimers Dis. 10: 223-253 (2006).

• You G. Towards an understanding of organic anion transporters: structure-function relationships. Med. Res. Rev. 24: 762-774 (2004). *

• Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 9: 597-624 (2008).

• Zalups RK, Ahmad S. Homocysteine and the renal epithelial transport and toxicity of inorganic mercury: role of basolateral transporter organic anion transporter 1. J. Am. Soc. Nephrol. 15: 2023-2031 (2004). *

• Zalups RK, Aslamkhan AG, Ahmad S. Human organic anion transporter 1 mediates cellular uptake of cysteine-S conjugates of inorganic mercury. Kidney Int. 66: 251-261 (2004). *

• Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem. J. 369: 23-30 (2003). *

• Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem. 276: 46400-46407 (2001). *

• Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 60: 4779-4784 (2000). *

• Zhang DW, Nunoya K, Vasa M, Gu HM, Theis A, Cole SP, Deeley RG. Transmembrane helix 11 of multidrug resistance protein 1 (MRP1/ABCC1): identification of polar amino acids important for substrate specificity and binding of ATP at nucleotide binding domain 1. Biochemistry 43: 9413-9425 (2004). *

• Zhang HX, Wang LS. Effect of genetic polymorphism on the activity of drug transporters and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban 33: 765-768 (2008).

• Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A, Liu ZQ, Deng S, Huang YF, Xu LY, Zhou HH. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin. Exp. Pharmacol. Physiol. 34: 1240-1244 (2007). *

• Zhang Y, Li W, Vore M. Translational regulation of rat multidrug resistance-associated protein 2 (Mrp2) expression is mediated by upstream open reading frames (uORFs) in the 5' untranslated region (UTR). Mol. Pharmacol. 71: 377-383 (2007). *

• Zhou F, Pan Z, Ma J, You G. Mutational analysis of histidine residues in human organic anion transporter 4 (hOAT4). Biochem. J. 384: 87-92 (2004). *

• Zhou F, Tanaka K, Pan Z, Ma J, You G. The role of glycine residues in the function of human organic anion transporter 4. Mol. Pharmacol. 65: 1141-1147 (2004). *

• Zhou F, You G. Molecular insights into the structure-function relationship of organic anion transporters OATs. Pharm. Res. 24: 28-36 (2007). *

• Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 15: 1981-2039 (2008).

• Zimniak P. Dubin-Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin. Liver Dis. 13: 248-260 (1993).

• Zinchuk V, Zinchuk O, Akimaru K, Moriya F, Okada T. Ethanol consumption alters expression and colocalization of bile salt export pump and multidrug resistance protein 2 in the rat. Histochem. Cell Biol. 127: 503-512 (2007). *

• Zinchuk VS, Okada T, Akimaru K, Seguchi H. Asynchronous expression and colocalization of Bsep and Mrp2 during development of rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G540-G548 (2002). *

• Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 38: 717-727 (2003). *

• Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33: 633-646 (2001). *

• Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25: 367-379 (2005). *

• Zsembery A, Thalhammer T, Graf J. Bile formation: a concerted action of membrane transporters in hepatocytes and cholangiocytes. News Physiol. Sci. 15: 6-11 (2000). *

Number of references = 503

www psc-literature.org